Anivive Lifesciences

About Anivive Lifesciences

Anivive Lifesciences, Inc., founded in 2015 by Dylan Balsz and Warren Rickard, operates as a pet pharmaceutical company with a focus on accelerating the development of new therapeutics for cats and dogs. The company is headquartered in Long Beach, California. The founders' backgrounds are complementary; Dylan Balsz, serving as CEO, brings experience from the software and technology sector, while Warren Rickard, the Chief Scientific Officer, has a deep history in veterinary medicine and clinical research, previously working at institutions like the USC Keck School of Medicine. This blend of expertise underpins the company's core strategy.

Anivive's business model centers on identifying, acquiring, and developing promising treatments that have been deprioritized by larger pharmaceutical companies, often because they target diseases considered too rare to be commercially viable in human medicine. The company utilizes a proprietary software platform that leverages artificial intelligence to predict which of these human drugs might be effective for specific animal diseases. This data-driven approach aims to significantly reduce the time and cost associated with veterinary drug development, a process that can traditionally take over a decade and cost more than $100 million. Anivive's clients are primarily veterinarians, to whom they provide these novel treatments for unmet medical needs in pets.

One of the company's notable products is for the treatment of Valley Fever (coccidioidomycosis), a fungal infection that affects dogs. They have also been developing a potential treatment for feline sarcoma and have a broader pipeline that includes therapeutics for canine lymphoma, arthritis, and inflammatory diseases. By focusing on repurposing existing, well-understood compounds, Anivive mitigates some of the early-stage risks inherent in drug discovery. The company has secured significant funding to advance its clinical trials, including a notable $10 million in a Series A round.